Arcus Biosciences Announces Participation at Three Investor Conferences in November 2018

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the management team will participate at the following upcoming investor conferences:

• Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018, at 4:35 pm MT.
• Piper Jaffray 30th Annual Healthcare Conference in New York City, NY on Tuesday, November 27, 2018, at 3:50 pm ET.
• Evercore ISI HealthCONx in Boston, MA on Wednesday, November 28, 2018, at 10:15 am ET.

To access the live audio webcast of the presentations, please visit the “Events & Presentations” section of the Arcus website at https://investors.arcusbio.com/investors/events-and-presentations. A replay of the webcast will be available for 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates. Arcus’s other programs include AB154, an anti-TIGIT antibody, which is in a Phase 1 trial to evaluate AB154 as monotherapy and in combination with AB122, and AB680, a small molecule inhibitor of CD73, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181101006030/en/